Yes I understood that those were possible future indications for the use of Cx601, and that could lead to an expansion of income to TiGenix/Takeda and the royalty stream to Mesoblast.
I used a document from the European Medicines Agency (EMA) help me understand how Alofisel was going to be administered, p. 2, sec. 4 Clinical Particulars, and especially the section Method of Adminstration on pages 3 and 4. Extremely graphic too but in the textual sense
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR__Product_Information/human/004258/WC500246474.pdf
Finally you wrote;
"As you can see, these are two separate disease targets with two separate MSC products trying to address them."
That is what I was trying to convey with the following in my first post above;
"Why would MSB bother to continue with a Crohn’s Disease treatment when Takeda have one about to be released across the EU? Because the targets of the treatment are different. I have bolded some bits for clarification."
For added clarity I could have included the primary and secondary outcomes of the MSB Crohn's Disease Trial, so I will here;
"Current Primary outcome measures:
Disease remission (CDAI at or below 150) [ Time Frame: 28 days ]
Current Secondary outcome measures:
From;
- Disease improvement (Reduction by at least 100 points in CDAI) [ Time Frame: 28 days ]
- Improvement in quality of life (IBDQ) [ Time Frame: 28 days ]
- Reduction in number of draining fistulas [ Time Frame: 28 days ]"
https://www.clinicaltrials.gov/ct2/show/record/NCT00482092
So the primary aim is the Induction of Remission as defined, the secondary less desirable but definitely OK effects include but are not limited to, a reduction in the number of draining fistulas. The specific type of fistula is not mentioned in the trial description however the eligibility criteria includes;
"endoscopically or radiographically confirmed Crohn's disease of ileus or colon or both"
After a little searching I think that means enterocutaneous fistulas are covered, however the other types of gastrointestinal fistula are not listed as a cause for exclusion. Whether or not a person would have multiple types present simultaneously I have no idea.
As you might infer from the above, I have no medical training at all. I'm just a share holder who likes to do a bit of that DYOR thing.![]()
- Forums
- ASX - By Stock
- MSB
- Licensees and MSCs
Licensees and MSCs, page-5
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.26 |
Change
-0.050(3.83%) |
Mkt cap ! $1.432B |
Open | High | Low | Value | Volume |
$1.27 | $1.30 | $1.17 | $21.32M | 17.21M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 5460 | $1.25 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.26 | 978 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 5460 | 1.250 |
3 | 38390 | 1.245 |
4 | 165443 | 1.240 |
3 | 125898 | 1.235 |
6 | 135812 | 1.230 |
Price($) | Vol. | No. |
---|---|---|
1.255 | 978 | 1 |
1.260 | 191681 | 5 |
1.265 | 127480 | 6 |
1.270 | 136662 | 4 |
1.275 | 146158 | 3 |
Last trade - 16.10pm 24/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
FHE
FRONTIER ENERGY LIMITED
Adam Kiley, CEO
Adam Kiley
CEO
Previous Video
Next Video
SPONSORED BY The Market Online